Tech Company Financing Transactions
CardioDx Funding Round
On 12/18/2014, CardioDx secured $35 million in Series D funding from Aimco and private investors.
Transaction Overview
Company Name
Announced On
12/18/2014
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series D
Investors
Proceeds Purpose
The funds will enable CardioDx to broaden the commercial use of Corus CAD, the only clinically validated blood test that uses age, sex and gene expression to measure the likelihood of obstructive coronary artery disease in symptomatic patients, as well as to augment the company's research efforts to improve healthcare quality and efficiency through the development of additional genomic tests for coronary artery disease.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
600 Saginaw Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, is committed to improving the quality of care for patients with cardiovascular disease through the research, development, and validation of clinically important genomic tests.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Khush Mehta
Chief Financial Officer
Timothy Henn
Chief Medical Officer
Mark Monane
VP - Bus. Development
Susan Daniels
VP - Bus. Development
David Levison
VP - R & D
James Wingrove
VP - Sales
Duane Williams
Browse more venture capital transactions:
Prev: 12/18/2014: theSkimm venture capital transaction
Next: 12/19/2014: Zeel Networks venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs